Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates - Scorecard - MDSpire

Sustained Efficacy of AAV Vector-Based SARS-CoV-2 Prevention in Murine Models and Non-Human Primates

  • By

  • Ekaterina I. Ryabova

  • Artem A. Derkaev

  • Ilias B. Esmagambetov

  • Mikhail A. Dovgiy

  • Ilya V. Gordeychuk

  • Inna V. Shuliakova

  • Rosa M. Hossain

  • Anton A. Blinov

  • Anna A. Iliukhina

  • Daria M. Grousova

  • Ilya D. Zorkov

  • Daria V. Avdoshina

  • Stanislav A. Gulyaev

  • Vasiliy D. Apolokhov

  • Tatiana V. Gulyaeva

  • Irina A. Favorskaya

  • Dmitry V. Shcheblyakov

  • Alexander L. Gintsburg

  • Denis Y. Logunov

  • June 4, 2026

Share

Clinical Scorecard: Sustained Efficacy of AAV Vector-Based SARS-CoV-2 Prevention in Murine Models and Non-Human Primates

At a Glance

CategoryDetail
Condition
Key MechanismsRecombinant adeno-associated virus (rAAV) delivery of neutralizing antibodies (source needed).
Target Population
Care Setting

Key Highlights

  • Single intramuscular administration of rAAV-P2C5-Fc provides long-term protective efficacy against SARS-CoV-2 variants (source needed).
  • Antibody levels remained protective for over 480 days in mice and up to 1,120 days in marmosets (source needed).
  • Biodistribution analysis showed minimal off-target spread of rAAV (source needed).
  • Moderate anti-AAV capsid antibody responses were detected; anti-drug antibodies against P2C5-Fc remained undetectable (source needed).

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Mice and common marmosets in preclinical studies

          Rapid onset and sustained expression of neutralizing antibodies following a single administration.

          Clinical Best Practices

            Related Resources & Content

              Original Source(s)

              Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

              • by Ekaterina I. Ryabova, Artem A. Derkaev, Ilias B. Esmagambetov, Mikhail A. Dovgiy, Ilya V. Gordeychuk, Inna V. Shuliakova, Rosa M. Hossain, Anton A. Blinov, Anna A. Iliukhina, Daria M. Grousova, Ilya D. Zorkov, Daria V. Avdoshina, Stanislav A. Gulyaev, Vasiliy D. Apolokhov, Tatiana V. Gulyaeva, Irina A. Favorskaya, Dmitry V. Shcheblyakov, Alexander L. Gintsburg, Denis Y. Logunov

              • June 4, 2026

              Related Content

              Comparison of the protective effect of human respiratory syncytial virus Pre-F protein combined with different adjuvants in BALB/c mice

              Conformational bias in SARS-CoV-2 Spike CD4+ T-cell epitope dominance

              Novel Recruitment, Data Collection, and Safety Reporting Methods in the Era of COVID-19: Design of a Post-Emergency Use Authorization COVID-19 Vaccination Safety-Surveillance Study